Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

June 15, 2024

Study Completion Date

June 15, 2024

Conditions

Kidney Transplantation

Interventions

DRUG

SHR-2106 injection or placebo

starting dose from 50 mg

DRUG

SHR-2106 injection or placebo

starting dose from 300 mg

Trial Locations (1)

The third xiangya hospital of central south univercity, Changsha

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY